Kedye-B (02487) rose more than 8% in the afternoon, as of the time of publication, up 4.99% to HK$16, with a turnover of HK$5.435 million.
According to the Intelligence Financial APP, Kedye-B (02487) rose more than 8% in the afternoon, up 4.99% to HK$16, with a turnover of HK$5.435 million as of the time of publication.
On the news front, Kedye announced completion of the first subject enrollment in Phase I clinical trial of CU-10101, a novel topical small molecule drug for the treatment of mild to moderate atopic dermatitis. CU-10101 is a non-steroidal, small molecule drug for the treatment of mild to moderate atopic dermatitis. Treatment options for atopic dermatitis are limited and primarily include corticosteroids, calcium calmodulin kinase inhibitors, systemic immunosuppressants, targeted biologics, and small molecule drugs.
